Drug-induced lysosomal storage of sulphated glycosaminoglycans

General Pharmacology

Volumn 27, Issue 8, 1996, Pages 1317-1324

  Fischer, Jens ^a   Lüllmann, Heinz ^a   Lüllmann Rauch, Renate ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 BIS(2 DIETHYLAMINOETHOXY) 9,10 ANTHRAQUINONE; 2,7 BIS[4 (1 PIPERIDYL)BUTYRYL]FLUORENE; CL 90100; CL 90199; DERMATAN SULFATE; GLYCOSAMINOGLYCAN POLYSULFATE; HEXESTROL BIS(2 DIETHYLAMINOETHYL) ETHER; IMMUNOMODULATING AGENT; LYSOSOME ENZYME; MEPACRINE; RMI 11002; TILORONE; TILORONE DERIVATIVE; UNCLASSIFIED DRUG;

CELL CULTURE; CELL INCLUSION; COMPLEX FORMATION; CROSS LINKING; CYTOLOGY; DRUG ACCUMULATION; DRUG INDUCED DISEASE; FIBROBLAST; HUMAN; KERATOPATHY; LYSOSOME STORAGE DISEASE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; REVIEW; STRUCTURE ACTIVITY RELATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CATTLE; DERMATAN SULFATE; GLYCOSAMINOGLYCANS; HUMANS; LIVER; LYSOSOMAL STORAGE DISEASES; LYSOSOMES; RATS; TILORONE; TISSUE DISTRIBUTION;

EID: 0030561552     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(96)00150-4     Document Type: Review

References (57)

1. Bispinck F., Fischer J. and Lüllmann-Rauch R. (1995) Drug-induced glycosaminoglycan-storage in lysosomes of cultured fibroblasts and intralysosomal accumulation of drug were not reversible within 10 days. Naunyn-Schmiedebergs Arch. Pharmacol. 351 (Suppl.), R 56 (Abstract).
2. Brown J. A., Novak E. K. and Swank R. T. (1984) Effects of ammonia on processing and secretion of precursor and mature lysosomal enzyme from macrophages of normal and pale ear mice: Evidence for two distinct pathways. J. Cell Biol. 100, 1894-1904.
3. Brown W. J., Goodhouse J. and Farquhar M. G. (1986) Mannose-6-phosphate receptors for lysosomal enzymes cycle between the Golgi complex and endosomes. J. Cell Biol. 103, 1235-1247.
4. Burmester J., Handrock K. and Lüllmann-Rauch R. (1990) Cultured corneal fibroblasts as a model system for the demonstration of drug-induced mucopolysaccharidosis. Arch. Toxicol. 64, 291-298.
5. DeDuve C., DeBarsy T., Poole B., Trouet A., Tulkens P. and Van Hoof F. (1974) Lysosomotropic agents. Biochem. Pharmacol. 23, 2495-2531.
6. Fischer J. (1995) Tilorone-induced lysosomal storage of glycosaminoglycans in cultured corneal fibroblasts: biochemical and physicochemical investigations. Biochem. J. 312, 215-222.
7. Fischer J. (1996a) Drug-induced glycosaminoglycan storage: Dose-dependent changes in the pattern of accumulated glycosaminoglycans in cultured bovine and human fibroblasts. Biochem. Pharmacol. (in press).
8. Fischer J. (1996b) Degradation of free glycosaminoglycan chains is inhibited by two immunomodulatory compounds in cultured fibroblasts. Naunyn-Schmiedebergs Arch.Pharmacol., 353(Suppl.), R78. (Abstract).
9. Fischer J., Hein L., Lüllmann-Rauch R. and von Witzendorff B. (1996a) Tilorone-induced lysosomal lesions: The bisbasic character of the drug is essential for its high potency to cause storage of sulphated glycosaminoglycans. Biochem. J. 315, 169-375.
10. Fischer J., Lüllmann-Rauch R., Stubbe E. and von Witzendorff B. (1996b) Lysosomal storage of sulfated glycosaminoglycans induced by two bisaminomethyl anthrachinones. Arch. Toxicol., 70, 373-379.
11. Gaur V. and Chandra P. (1976) Tilorone hydrochloride: Its pharmacokinetic parameters and pharmacodynamic effects. In Chemotherapy, Cancer Chemotherapy II, Vol. 8 (Edited by Hellman K. and Connors T. A.) pp. 43-50, Plenum Press, New York.
12. Goldman J. N., Benedek G. B., Dohlman C. H. and Kravitt B. (1968) Structural alterations affecting transparency in swollen corneas. Invest. Ophthalmol. 7, 501-519.
13. Gonzalez-Noriega A., Grub J. H., Talkad V. and Sly W. S. (1980) Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by impairing receptor recycling. J. Cell Biol. 85, 839-852.
14. Grave S., Lüllmann H., Lüllmann-Rauch R., Osterkamp G. and Prokopek M. (1992) Induction of mucopolysaccharidosis in rats by treatment with immunostimulatory acridine derivatives. Toxicol. Appl. Pharmacol. 114, 215-224.
15. Gupta D. K., Gieselmann V., Hasilik A. and von Figura K. (1984) Tilorone acts as a lysosomotropic agent in fibroblasts. Hoppe-Seylers Z. Physiol. Chem. 365, 859-866.
16. Handrock K., Laschke A., Lüllmann-Rauch R., Vogt R. D. and Ziegenhagen M. (1992) Lysosomal storage of sulfated glycosaminoglycans in cultured fibroblasts exposed to immunostimulatory acridine derivatives. Toxicol. Appl. Pharmacol. 114, 204-214.
17. Handrock K., Lüllmann-Rauch R. and Vogt R. D. (1993) Drug-induced lysosomal storage of sulfated glycosaminoglycans. Studies on the underlying structure-activity relationships. Toxicology 85, 199-213.
18. Hasilik A. and Neufeld E. F. ( 1980) Biosynthesis of lysosomal enzymes in fibroblasts. Synthesis as precursors of higher molecular weight. J. Biol. Chem. 255, 4937-4945.
19. Haust M. D. (1973) The genetic mucopolysaccharidoses. Int. Rev. Exp. Pathol. 12, 251-314.
20. Hein L. and Lüllmann-Rauch R. (1989) Mucopolysaccharidosis and lipidosis in rats treated with tilorone analogues. Toxicology 58, 145-154.
21. Hoenig V. and Préteux F. (1977) Hepatic disposition of tilorone hydrochloride in the rat. Xenobiotica 7, 339-344.
22. Horstmann G. and Lüllman-Rauch R. (1985) Mucopolysaccharidosis-like alterations in cardiac valves of rats treated with tilorone. Virchows Arch. Cell Pathol. 48, 33-45.
23. Jackson R. L., Busch S. J. and Cardin A.D. (1991) Glycosaminoglycans: Molecular properties, protein interactions, and role in physiological processes. Physiol. Rev. 71, 481-539.
24. Kjellén L. and Lindahl U. (1991 ) Proteoglycans: Structures and interactions. Ann. Rev. Biochem. 60, 443-475.
25. Klintworth G. K. (1982) Disorders of glycosaminoglycans (mucopolysaccharides and proteoglycans. In Pathobiology of Ocular Disease. Part B (Edited by Gainer A. and Klintworth G. K.) pp. 863-895. Marcel Dekker, New York.
26. Lev R. and Spicer S. S. (1964) Specific staining of sulphate groups with alcian blue at low pH. J. Histochem. Cytochem. 12, 309.
27. Levine S. and Sowinski R. (1977) T-lymphocyte depletion and lesions of choroid plexus and kidney induced by tertiary amines in rats. Toxicol. Appl. Pharmacol. 40, 147-159.
28. Lüllmann H., Lüllmann-Rauch R. and Wassermann O. (1978) Lipidosis induced by amphiphilic cationic drugs. Biochem. Pharmacol. 27, 1103-1108.
29. Lüllmann-Rauch R. (1979) Drug-induced lysosomal storage disorders. In Lysosomes in Applied Biology and Therapeutics. Vol. 6 (Edited by Dingle J. T., Jacques P. J. and Shaw I. H.) pp. 49-130. North-Holland, Amsterdam.
30. Lüllmann-Rauch R. (1982) Histochemical evidence for lysosomal storage of acid glycosaminoglycans in splenic cells of rats treated with tilorone. Histochemistry 76, 71-87.
31. Lüllmann-Rauch R. (1983) Tilorone-induced lysosomal storage mimicking features of mucopolysaccharidosis and of lipidosis in rat liver. Virchows Arch. Cell Pathol. 44, 355-368.
32. Lüllmann-Rauch R. (1986) Keratopathy in rats aftet treatment with tilorone. Graefes Arch. Clin. Exp. Ophthalmol. 224, 377-383.
33. Lüllmann-Rauch R. (1987) Lysosomal storage of sulfated glycosaminoglycans in renal interstitial cells of rats treated with tilorone. Cell Tissue Res. 250, 641-648.
34. Lüllmann-Rauch R. (1989) Experimental mucopolysaccharidosis: Preservation and ultrastructural visualization of intralysosomal glycosaminoglycans by use of the cationic dyes cuprolinic blue and toluidine blue. Histochemistry 93, 149-154.
35. Lüllmann-Rauch R. (1990) Mucopolysaccharidosis in ocular tissues as induced by amphiphilic di-cationic drugs. Lens Eye Tox. Res. 7, 263-279.
36. Lüllmann-Rauch R. (1994) Drug-induced intralysosomal storage of sulfated glycosaminoglycans (GAGs): A methodical pitfall occurring with acridine derivatives. Exp. Toxic. Pathol. 46, 315-322.
37. Lüllmann-Rauch R. and von Witzendorff B. ( 1996) Lysosomal storage of sulphated glycosaminoglycans induced by dicationic amphiphilic drug molecules: Significance of the central planar ring system. Pharmacol. Toxicol., 79, 109-113.
38. Lüllmann-Rauch R. and Ziegenhagen M. (1991) Drug-induced lysosomal storage of sulfared glycosaminoglycans in cultured bovine and human fibroblasts. Virchows Arch. Cell Pathol. 60, 99-104.
39. Lüllmann-Rauch R., Michel G. and Peters A. (1988) Mucopolysaccharidosis-like cellular alterations in chondrocytes of rats treated with tilorone. Exp. Molec. Pathol. 49, 279-289.
40. Lüllmann-Rauch R., Peters A. and Schleicher A. (1992) Osteopenia in rats with drug-induced mucopolysaccharidosis. Arzneim.-Forsch. 42, 559-566.
41. Lüllmann-Rauch R., Pods R. and von Witzendorff B. (1995) Tilorone-induced lysosomal storage of sulphated glycosaminoglycans can be dissociated from tilorone-induced enhancement of lysosomal enzyme secretion. Biochem. Pharmacol. 49, 1223-1233.
42. Lüllmann-Rauch R., Pods R. and von Witzendorff B. (1996) The antimalarials quinacrine and chloroquine induce weak lysosomal storage of sulphated glycosaminoglycans in cell culture and in vivo. Toxicology 110, 27-37.
43. MacIntyre A. and Cutler D. J. (1988a) The potential role of lysosomes in tissue distribution of weak bases. Biopharmac. Drug Dispos. 9, 513-526.
44. MacIntyre A. and Cutler D. J. (1988b) Role of lysosomes in hepatic accumulation of chloroquine. J. Pharmac. Sci. 77, 196-199.
45. Mason R. J., Walker S. R., Shields B. A., Henson J. E. and Williams M. C. (1985) Identification of rat alveolar type II epithelial cells with a tannic acid and polychrome stain. Am. Rev. Respir. Dis. 131, 786-788.
46. Neufeld E. F. and Muenzer J. (1995) The mucopolysaccharidoses. In The Metabolic and Molecular Bases of Inherited Disease. Vol. 2 (Edited by Scriver C. R., Beauder A. L., Sly W. S. and Valle D.) pp. 2465-2493. McGraw-Hill, New York.
47. Ohkuma S. and Poole B. (1978) Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc. Not. Acad. Sci. USA 75, 3327-3331.
48. Prokopek M. (1991) The tilorone-induced mucopolysaccharidosis in rats. Biochemical investigations. Biochem. Pharmacol. 42, 2187-2191.
49. Regelson W. (1981) The biological activity of the synthetic polyanion, pyran copolymer (diveema, MVE, 46015) and the heterocyclic bis DEAE fluorenone derivative, tilorone and congeners: Chemical and laboratory effects of these agents as modulators of host resistance. Pharmacol. Ther. 15, 1-44.
50. Renteria V. G., Ferrans V. J. and Roberts W. C. (1976) The heart in the Hurler syndrome. Am. J. Cardiol 38, 487-501.
51. Scott J. E. and Dorling J. (1965) Differential staining of acid glycosaminoglycans (mucopolysaccharides) by Alcian blue in salt solutions. Histochemistry 5, 221-233.
52. Scott J. E., Orford C. R. and Hughes E. W. (1981) Proteoglycan-collagen arrangements in developing rat tail tendon. Biochem. J. 195, 573-581.
53. Seglen P. O. (1983) Inhibitors of lysosomal function. Meth. Enzymol. 96, 737-764.
54. Spranger J. W. and von Germar R. (1967) Mucopolysaccharid-Suchtest. Clin. Pediat. 6, 659-660.
55. Weiss J. N., Ochs A. L., Abedi S. and Selhorst J. B. (1980a) Retinopathy after tilorone hydrochloride. Am. J. Ophthalmol 90, 846-853.
56. Weiss J. N., Weinberg R. S. and Regelson W. (1980b) Keratopathy after oral administration of tilorone hydrochloride. Am. J. Ophthalmol. 89, 46-53.
57. Wenk E. J., Levine S. and Hoenig E. M. (1979) Fine structure of contrasting choroid plexus lesions caused by tertiary amines or cyclophosphamide. J. Neuropathol. Exp. Neurol. 38, 1-9.